Safety board clears TxCell to restart Ovasave study that was halted last year
TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.
TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.
Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021.
Thermo Fisher Scientific is to buy FEI Company for $4.2bn saying it will drive adoption of FEI’s technologies among its life sciences customers, particularly in biopharma.
Indian drugmaker Biocon has been given the go-ahead to expand a biopharmaceutical manufacturing facility in Bangalore.